Costs per DALYs Averted of Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccine in Elderly Population in Thailand

Jadesada  Lertsirimunkong; Wiwat  Thavornwattanayong; Panasorn  Hirunkanakorn; Rujipas  Buranapatanapong; Sukanya  Jermtienchai; Nion  Mingmoree

doi:10.33192/Smj.2021.34

Costs per DALYs Averted of Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccine in Elderly Population in Thailand

Authors

Jadesada Lertsirimunkong Department of Pharmacy Administration, College of Pharmacy, Rangsit University, Pathum Thani, Thailand http://orcid.org/0000-0003-2930-8810
Wiwat Thavornwattanayong Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand http://orcid.org/0000-0002-6617-8587
Panasorn Hirunkanakorn Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand http://orcid.org/0000-0002-7883-2363
Rujipas Buranapatanapong Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand http://orcid.org/0000-0001-5761-2938
Sukanya Jermtienchai Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand http://orcid.org/0000-0001-7471-2455
Nion Mingmoree Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand http://orcid.org/0000-0001-7866-3734

DOI:

https://doi.org/10.33192/Smj.2021.34

Keywords:

Cost-effectiveness, DALYs averted, Influenza vaccine, Influenza, Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

Abstract

Objective: Influenza is an infection of the respiratory system with a high annual incident rate. Influenza vaccine
can reduce the severity of influenza and prevent transmission of the virus. Influenza vaccines in Thailand are the
Trivalent Influenza Vaccine (TIV) and the Quadrivalent Influenza Vaccine (QIV). The cost and the effectiveness of
the QIV in preventing transmission of the virus are greater than the TIV. Until now, no studies have been conducted
to compare the economic impact of using QIV or TIV. This study aimed to evaluate the economic effects of using
QIV versus TIV in Thai populations age 60 years and over.
Materials and Methods: The study was carried out from a societal perspective for cost per DALYs averted. A decision
tree model was used to analyse the costs and DALYs averted of Thais after they received the vaccine.
Results: In a period of one year, it was found that in Thais age 60 years and over, the total cost of TIV was 2,445.19
baht with 0.0094 DALYs and total cost of the QIV was 2,629.28 baht with 0.0082 DALYs and the incremental costeffectiveness
ratio (ICER) of the QIV was 158,489.24 baht per DALYs averted. The acceptability curves demonstrated
that the probability of QIV being cost-effective was 95% of the willingness to pay, being 1.2 times the Thai gross
national income per capita.
Conclusion: Therefore, in Thai people age over 60 years and over, QIV is more cost-effective than TIV. The results
of this study can be used by policymakers to help inform their decisions about which influenza vaccine is more
cost-effective.

Downloads

Published

23-03-2021

How to Cite

Lertsirimunkong, J. ., Thavornwattanayong, W. ., Hirunkanakorn, P. ., Buranapatanapong, R. ., Jermtienchai, S. ., & Mingmoree, N. . (2021). Costs per DALYs Averted of Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccine in Elderly Population in Thailand. Siriraj Medical Journal, 73(4), 259–267. https://doi.org/10.33192/Smj.2021.34

Download Citation

Issue

Vol. 73 No. 4 (2021): April

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.